1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes and survival in newly diagnosed, older, acute myeloid leukemia patients from the beat AML master trial in the venetoclax/azacitidine age
    Meeting Abstract

    Borate, U.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics
    Meeting Abstract

    Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Divergent population dynamics and gene signaling in monocytes distinctly influence responses to CD19-targeted CAR T-cells in relapsed/refractory B-NHL
    Meeting Abstract

    Blumenberg, V.; Kazerani, M.; Straub, T.; Corrado, F.; Borisov, V.; Baumann, S.; Busch, G.; Wulf, J.; Petrera, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Validation of dynamic deep learning for the prediction of cancer-associated thrombosis
    Meeting Abstract

    Mantha, S.; Singh, R.; Zwicker, J. I.; Li, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Proteolytic control and therapeutic targeting of oncogenic gene expression in acute myeloid leukemia
    Meeting Abstract

    Uni, M.; Steinberg, A. P.; Slavit, A.; Rha, S.; Cheng, S.; Schmalbrock, L. K.; Su, J.; Ma, J.; McPherson, A.; Mullighan, C. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Targeting PERK arm of unfolded protein response helps to eliminate therapy-induced residual senescent-like acute myeloid leukemia cells
    Meeting Abstract

    Poigaialwar, G.; Takao, S.; Chaudhry, S.; Schmalbrock, L. K.; Gupta, V.; Kentsis, A.; Aguirre-Ghiso, J. A.; Konopleva, M.; Sosa, M. S.; Skwarska, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison
    Meeting Abstract

    Lopez-Muñoz, N.; Bar, N.; Diels, J.; van Sanden, S.; Mendes, J.; Lee, S.; Hernando, T.; Lendvai, N.; Patel, N.; Ishida, T.; more...
    Blood (2024)

    Fulltext@MSK | Save